New mRNA vaccine combo takes on tough lung cancer in phase 2 trial
NCT ID NCT07221474
First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This Phase 2 trial tests whether adding a personalized mRNA vaccine (V940) to standard pembrolizumab and chemotherapy helps people with newly diagnosed metastatic squamous non-small cell lung cancer live longer and keep the cancer from growing. About 180 participants will receive either the vaccine combo or a placebo with the same standard therapy. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- V940 (mRNA-4157, intismeran autogene) plus pembrolizumab and chemotherapy
- What this could lead to
- If it works, this could lead to a new first-line treatment that helps people with metastatic squamous lung cancer live longer and delay cancer growth.
- What could go wrong
- This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. The added mRNA vaccine may not improve outcomes over standard chemo-immunotherapy and could cause additional side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ankara Bilkent Şehir Hastanesi ( Site 1402)
RECRUITINGAnkara, 06800, Turkey (Türkiye)
-
Asan Medical Center ( Site 0503)
RECRUITINGSeoul, 05505, South Korea
-
Bradford Hill Norte ( Site 0308)
RECRUITINGAntofagasta, 1263521, Chile
-
Bradfordhill ( Site 0301)
RECRUITINGSantiago, Region M. de Santiago, 8420383, Chile
-
CHU GABRIEL MONTPIED ( Site 0802)
RECRUITINGClermont-Ferrand, Puy-de-Dome, 63001, France
-
Centre Georges François Leclerc ( Site 0805)
RECRUITINGDijon, Cote-d Or, 21000, France
-
Centro de Estudios Clínicos SAGA ( Site 0307)
RECRUITINGSantiago, Region M. de Santiago, 7500653, Chile
-
Chang Gung Medical Foundation-Linkou Branch ( Site 0605)
RECRUITINGTaoyuan, 33305, Taiwan
-
China Medical University Hospital ( Site 0606)
RECRUITINGTaichung, 404, Taiwan
-
Chungbuk National University Hospital-Internal medicine ( Site 0501)
RECRUITINGCheongju-si, North Chungcheong, 28644, South Korea
-
Cleveland Clinic - Ohio ( Site 0016)
RECRUITINGCleveland, Ohio, 44195, United States
-
Clinica Adventista Belgrano ( Site 0206)
RECRUITINGCaba., Buenos Aires F.D., C1430EGF, Argentina
-
FALP ( Site 0300)
RECRUITINGSantiago, Region M. de Santiago, 7500921, Chile
-
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 1000)
RECRUITINGMilan, 20133, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1001)
RECRUITINGRoma, 00168, Italy
-
Fundacion Estudios Clinicos ( Site 0207)
RECRUITINGRosario, Santa Fe Province, S2000DSV, Argentina
-
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025)
RECRUITINGCorvallis, Oregon, 97330, United States
-
Hacettepe Universitesi Tıp Fakultesi ( Site 1400)
RECRUITINGAnkara, 06230, Turkey (Türkiye)
-
Hospital Clinico San Carlos... ( Site 1313)
RECRUITINGMadrid, 28040, Spain
-
Hospital Italiano de Buenos Aires ( Site 0200)
RECRUITINGCiudad Autonoma de Buenos Aires., Buenos Aires, C1199ABB, Argentina
-
Hospital Jerez de la Frontera-UGC Oncología ( Site 1315)
RECRUITINGJerez de la Frontera, Cadiz, 11407, Spain
-
Hospital Ramon y Cajal ( Site 1314)
RECRUITINGMadrid, 28034, Spain
-
Hospital Universitari Vall d''Hebron ( Site 1310)
RECRUITINGBarcelona, 08035, Spain
-
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1312)
RECRUITINGSeville, 41009, Spain
-
ICO L Hospitalet ( Site 1311)
RECRUITINGHospitalet, Barcelona, 08907, Spain
-
Institut de Cancérologie de l'Ouest ( Site 0801)
RECRUITINGAngers, Pays de la Loire Region, 49055, France
-
Instituto Alexander Fleming ( Site 0201)
RECRUITINGCiudad Autonoma de Buenos Aires, Buenos Aires, C1426ANZ, Argentina
-
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205)
RECRUITINGMar del Plata, Buenos Aires, B7600FZO, Argentina
-
Koç Üniversitesi Hastanesi ( Site 1403)
RECRUITINGIstanbul, 34010, Turkey (Türkiye)
-
Mackay Memorial Hospital ( Site 0604)
RECRUITINGTaipei, 104, Taiwan
-
Memorial Ankara Hastanesi ( Site 1401)
RECRUITINGAnkara, 06520, Turkey (Türkiye)
-
Moffitt Cancer Center ( Site 0021)
RECRUITINGTampa, Florida, 33612, United States
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1100)
RECRUITINGWarsaw, Masovian Voivodeship, 02-781, Poland
-
National Cancer Center ( Site 0504)
RECRUITINGGoyang-si, Kyonggi-do, 10408, South Korea
-
National Cheng Kung University Hospital ( Site 0601)
RECRUITINGTainan, 70403, Taiwan
-
National Taiwan University Cancer Center (NTUCC) ( Site 0600)
RECRUITINGTaipei, 106, Taiwan
-
New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001)
RECRUITINGAlbany, New York, 12206, United States
-
One Clinical Research ( Site 0402)
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Ospedale San Raffaele-Oncologia Medica ( Site 1002)
RECRUITINGMilan, 20132, Italy
-
Ospedale Santa Maria delle Croci-Dipartimento Oncoematologico ( Site 1004)
RECRUITINGRavenna, Emilia-Romagna, 48121, Italy
-
Princess Alexandra Hospital ( Site 0403)
RECRUITINGWoolloongabba, Queensland, 4102, Australia
-
Samsung Medical Center ( Site 0502)
RECRUITINGSeoul, 06351, South Korea
-
Sanatorio Parque ( Site 0203)
RECRUITINGRosario, Santa Fe Province, S2000DSV, Argentina
-
Seoul National University Bundang Hospital ( Site 0500)
RECRUITINGSeongnam-si, Kyonggi-do, 13620, South Korea
-
Swedish Medical Center-Swedish Cancer Institute ( Site 0023)
RECRUITINGSeattle, Washington, 98104, United States
-
Taipei Veterans General Hospital ( Site 0602)
RECRUITINGTaipei, 11217, Taiwan
-
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
RECRUITINGNashville, Tennessee, 37203, United States
-
Texas Oncology - Central/South Texas ( Site 8002)
RECRUITINGAustin, Texas, 78745, United States
-
Valley Health Systems - Ridgewood Campus ( Site 0010)
RECRUITINGParamus, New Jersey, 07652, United States
-
Virginia Cancer Specialists ( Site 0003)
RECRUITINGFairfax, Virginia, 22031, United States
-
Washington University School of Medicine ( Site 0024)
RECRUITINGSt Louis, Missouri, 63110, United States
-
Westmead Hospital ( Site 0400)
RECRUITINGWestmead, New South Wales, 2145, Australia
-
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1101)
RECRUITINGPoznan, Greater Poland Voivodeship, 60-569, Poland
-
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1102)
RECRUITINGPrzemyśl, Podkarpackie Voivodeship, 37-700, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outperform standard therapy for lung cancer?
- Can a novel drug combo outperform chemo in lung cancer?
- Can a new drug ASP388B take on advanced solid tumors?
- Could a cheaper copy of keytruda work just as well against cancer?
- New lung cancer cocktail aims to outperform current standard therapy
- New cocktail of immune drugs shows promise in lung cancer trial